Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.
https://www.pharmalive.com/wp-content/uploads/2021/10/Cipla-to-sell-Lillys-Trulicity-Humalog-diabetes-treatments-in-India-Reuters-10-4-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-01-28 13:21:002022-01-31 13:33:11Eli Lilly says FDA could deny expanded use of arthritis drug for eczema